Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 6, 2017, Pages 1412-1420

  Haskins Coulter, Tao ^a   Southern, Jo ^a   Andrews, Nick ^a   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Cervarix ; gardasil ; Human Papillomavirus (HPV) vaccine; reactogenicity; vaccine safety

Indexed keywords

ALUMINUM; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADJUVANT THERAPY; ADOLESCENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LOSS OF APPETITE; NONHUMAN; PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; SINGLE BLIND PROCEDURE; SKIN REDNESS; SWELLING; ADVERSE DRUG REACTION; CHILD; IMMUNOLOGY; PATHOLOGY; UNITED KINGDOM;

ADOLESCENT; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; PAPILLOMAVIRUS VACCINES; SINGLE-BLIND METHOD; UNITED KINGDOM;

EID: 85015633222     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1277846     Document Type: Article

References (35)

1. Human papillomavirus (HPV) immunisation programme review:2008 to 2014 - Publications - GOV.UK (Internet). Available from:https://www.gov.uk/government/publications/human-papillomavirus-hpv-immunisation-programme-review-2008-to-2014
2. Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, et al. A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12–15 Year Old Girls. Ellis RD, editor. PLoS One (Internet) 2013 (cited 2016Nov18); 8(5):e61825. Available from:http://dx.plos.org/10.1371/journal.pone.0061825; PMID:23650505; https://doi.org/10.1371/journal.pone.0061825
3. Smith A, Yarwood J, Salisbury DM. Tracking mothers' attitudes to MMR immunisation 1996–2006. Vaccine (Internet) 2007 (cited 2016Nov18); 25(20):3996-4002. Available from:http://linkinghub.elsevier.com/retrieve/pii/S0264410X07002241; PMID:17395344; https://doi.org/10.1016/j.vaccine.2007.02.071
4. Walsh CD, Gera A, Shah M, Sharma A, Powell JE, Wilson S. Public knowledge and attitudes towards Human Papilloma Virus (HPV) vaccination. BMC Public Health (Internet) 2008 (cited 2016Nov18); 8(1):368. Available from:http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-8-368; PMID:18947430; https://doi.org/10.1186/1471-2458-8-368
5. Noakes K, Yarwood J, Salisbury D. Parental response to the introduction of a vaccine against human papilloma virus. Hum Vaccin (Internet) 2015 (cited 2016Nov18); 2(6):243-8. Available from:http://www.landesbioscience.com/journals/vaccines/abstract.php?id= 3391; https://doi.org/10.4161/hv.2.6.3391
6. Medicines Agency E. HPV vaccines:EMA confirms evidence does not support that they cause CRPS or POTS (Internet). 2016 (cited 2016Nov19). Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/European_Commission_final_decision/WC500196773.pdf
7. Miranda S, Chaignot C, Collin C, Dray-Spira R, Weill A, Zureik M. Vaccination anti-HPV et risque de maladies auto-immunes:étude de cohorte française. Rev Epidemiol Sante Publique 2016; 64:S10; https://doi.org/10.1016/j.respe.2016.01.037
8. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden:cohort study. BMJ 2013; 347:f5906; PMID:24108159; https://doi.org/10.1136/bmj.f5906
9. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin (Internet) 2009 (cited 2016Nov18); 5(10):705-19. Available from:http://www.ncbi.nlm.nih.gov/pubmed/19684472; PMID:19684472; https://doi.org/10.4161/hv.5.10.9518
10. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT. Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions. Hum Vaccin (Internet) 2007 (cited 2016Nov18); 3(4):109-15. Available from:http://www.tandfonline.com/doi/abs/10.4161/hv.3.4.4058; PMID:17611417; https://doi.org/10.4161/hv.3.4.4058
11. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule. Hum Vaccin (Internet) 2011 (cited 2016Nov18); 7(12):1374-86. Available from:http://www.tandfonline.com/doi/abs/10.4161/hv.7.12.18322; PMID:22048171; https://doi.org/10.4161/hv.7.12.18322
12. Kim SC, Song YS, Kim YT, Kim YT, Ryu KS, Gunapalaiah B, Bi D, Bock HL, Park JS. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine:immunogenicity and safety in 15–25 years old healthy Korean women. J Gynecol Oncol (Internet) 2011 (cited 2016Nov18); 22(2):67. Available from:http://synapse.koreamed.org/DOIx.php?id = 10.3802/jgo.2011.22.2.67; PMID:21860731; https://doi.org/10.3802/jgo.2011.22.2.67
13. Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women. Clin Infect Dis (Internet) 2014 Jul 1 (cited 2016Nov18); 59(1):127-35. Available from:http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciu238; PMID:24723284; https://doi.org/10.1093/cid/ciu238
14. Leung TF, Liu AP-Y, Lim FS, Thollot F, Oh HML, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years:Results to month 12 from a randomized trial. Hum Vaccin Immunother (Internet) 2015 (cited 2016Nov18); 11(7):1689-702. Available from:http://www.tandfonline.com/doi/full/10.1080/21645515.2015.1050570; PMID:26062002; https://doi.org/10.1080/21645515.2015.1050570
15. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine (Internet) 2006 (cited 2016Nov19); 24(33–34):5937-49. Available from:http://www.ncbi.nlm.nih.gov/pubmed/16828940; PMID:16828940; https://doi.org/10.1016/j.vaccine.2006.06.005
16. Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, et al. Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine:A Randomized Trial in 10–25-Year-Old HIV-seronegative african girls and young women. J Infect Dis (Internet) 2013 (cited 2016Nov18); 207(11):1753-63. Available from:http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jis619; PMID:23242542; https://doi.org/10.1093/infdis/jis619
17. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years:4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet (Internet) 2014 (cited 2016Nov18); 384(9961):2213-27. Available from:http://linkinghub.elsevier.com/retrieve/pii/S014067361460920X; PMID:25189358; https://doi.org/10.1016/S0140-6736(14)60920-X
18. Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M, Levänen H, Tocklin T, Godeaux O, Lehtinen M, et al. Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years. J Adolesc Heal (Internet) 2009 (cited 2016Nov18); 44(1):33-40. Available from:http://linkinghub.elsevier.com/retrieve/pii/S1054139X08004345; https://doi.org/10.1016/j.jadohealth.2008.10.002
19. Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, Nam JH, Ahn WS, Choi HS, Ng T, et al. Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10–14 Years. J Korean Med Sci (Internet) 2010 (cited 2016Nov18); 25(8):1197. Available from:http://synapse.koreamed.org/DOIx.php?id=10.3346/jkms.2010.25.8.1197; PMID:20676333; https://doi.org/10.3346/jkms.2010.25.8.1197
20. Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, Wang J, Yang J, Xia G, Dai Q, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years. Hum Vaccin Immunother (Internet) 2014 (cited 2016Nov18); 10(7):1795-806. Available from:http://www.ncbi.nlm.nih.gov/pubmed/25424785; PMID:25424785; https://doi.org/10.4161/hv.28702
21. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention:a pooled analysis of 11 clinical trials. Hum Vaccin (Internet) 2009 (cited 2016Nov18); 5(5):332-40. Available from:http://www.ncbi.nlm.nih.gov/pubmed/19221517; https://doi.org/10.4161/hv.5.5.7211
22. Panagiotou OA, Befano BL, Gonzalez P, Rodríguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ, et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes:long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ 2015; 351:h4358; PMID:26346155; https://doi.org/10.1136/bmj.h4358
23. Garcia-Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin J-E, Tran PM, Behre U, Iturbe EB, Catteau G, Thomas F, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis–inactivated poliovirus vaccine to girls and young women. J Adolesc Heal (Internet) 2010 (cited 2016Nov18); 46(2):142-51. Available from:http://linkinghub.elsevier.com/retrieve/pii/S1054139X09006296; https://doi.org/10.1016/j.jadohealth.2009.11.205
24. Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine (Internet) 2010 (cited 2016Nov18); 28(18):3171-9. Available from:http://linkinghub.elsevier.com/retrieve/pii/S0264410X10002136; PMID:20189491; https://doi.org/10.1016/j.vaccine.2010.02.045
25. Wheeler CM, Harvey BM, Pichichero ME, Simon MW, Combs SP, Blatter MM, Marshall GS, Catteau G, Dobbelaere K, Descamps D, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 years of age. Pediatr Infect Dis J (Internet) 2011 (cited 2016Nov18); 30(12):e225-34. Available from:http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006454-201112000-00037; PMID:21817954; https://doi.org/10.1097/INF.0b013e31822d28df
26. Schmeink CE, Bekkers RLM, Josefsson A, Richardus JH, Berndtsson Blom K, David MP, Dobbelaere K, Descamps D. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine:Randomized study in healthy girls. Vaccine (Internet) 2011 (cited 2016Nov18); 29(49):9276-83. Available from:http://linkinghub.elsevier.com/retrieve/pii/S0264410X11012680; PMID:21856349; https://doi.org/10.1016/j.vaccine.2011.08.037
27. Leroux-Roels G, Haelterman E, Maes C, Levy J, De Boever F, Licini L, David MP, Dobbelaere K, Descamps D. Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given in an Accelerated Schedule Coadministered with the Human Papillomavirus Type 16/18 AS04-Adjuvanted Cervical Cancer Vaccine. Clin Vaccine Immunol (Internet) 2011 (cited 2016Nov18); 18(9):1510-8. Available from:http://cvi.asm.org/cgi/doi/10.1128/CVI.00539-10; PMID:21734063; https://doi.org/10.1128/CVI.00539-10
28. Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlán G, Silfverdal SA, Szüts P, O'Mahony M, David MP, Dobbelaere K, et al. Randomized Trial:Immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-Adjuvanted vaccine and combined Hepatitis A and B vaccine in girls. J Adolesc Heal (Internet) 2012 (cited 2016Nov18); 50(1):38-46. Available from:http://linkinghub.elsevier.com/retrieve/pii/S1054139X11003533; https://doi.org/10.1016/j.jadohealth.2011.10.009
29. Toft L, Storgaard M, Muller M, Sehr P, Bonde J, Tolstrup M, Østergaard L, Søgaard OS. Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults:A Randomized, Double-Blind Clinical Trial. J Infect Dis (Internet) 2014 (cited 2016Nov18); 209(8):1165-73. Available from:http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jit657; PMID:24273179; https://doi.org/10.1093/infdis/jit657
30. Vishram B, Byrne L, White J, Edelstein M. Human Papillomavirus (HPV) vaccination coverage in adolescent females in England:2014/15. 2015 (cited 2016Nov18); Available from:https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/487514/HPV_2014_15_ReportFinal181215_v1.1.pdf
31. Angelo M-G, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine:more than 4 years of experience. Pharmacoepidemiol Drug Saf (Internet) 2014 (cited 2016Nov18);23(5):456-65. Available from:http://doi.wiley.com/10.1002/pds.3593; PMID:24644078; https://doi.org/10.1002/pds.3593
32. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety. Pediatr Infect Dis J (Internet) 2015 (cited 2016Nov18); 34(9):983-91. Available from:http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006454-201509000-00017; PMID:26107345; https://doi.org/10.1097/INF.0000000000000793
33. Van Damme P, Leroux-Roels G, Simon P, Foidart J-M, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines:Results from two randomized trials. Vaccine (Internet) 2014 (cited 2016Nov18); 32(29):3694-705. Available from:http://linkinghub.elsevier.com/retrieve/pii/S0264410X14004095; PMID:24674663; https://doi.org/10.1016/j.vaccine.2014.03.040
34. Nelson EAS, Lam HS, Choi KC, Ho WCS, Fung LWE, Cheng FWT, Sung RY, Royals M, Chan PK. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18–26 years. Vaccine 2013; 31(34):3452-60; PMID:23770335; https://doi.org/10.1016/j.vaccine.2013.06.034
35. Gonçalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines:a systematic quantitative review. Brazilian J Infect Dis (Internet) 2014 (cited 2016Nov18); 18(6):651-9. Available from:http://linkinghub.elsevier.com/retrieve/pii/S1413867014000695; https://doi.org/10.1016/j.bjid.2014.02.005